| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5833675 | International Immunopharmacology | 2011 | 6 Pages |
Cholecystokinin octapeptide (CCK-8) is a typical brain-gut peptide that exerts a variety of physiological actions in both the peripheral and central nervous systems. Our laboratory has previously reported that CCK-8 produces immunoregulatory action through activating CCK receptor (CCK1R/CCK2R) expression on immune cell surfaces. In the present study, we investigated the effect of CCK-8 on immunoglobulin G1 (IgG1) production in lipopolysaccharide (LPS)-activated B cells in vitro. CCK-8 inhibited the proliferation and IgG1 mRNA expression of LPS-activated B cells and therefore inhibited IgG1 production. The mechanism may be associated with the regulation of CCK-8 on transcription factors Blimp1, Pax5, Xbp1 and Bcl6. CCK-8 inhibited the expression of Blimp1, while the effect on Pax5, Xbp1 and Bcl6 varied with time, suggesting that CCK-8 acted as a complex regulator of LPS-activated B cells. The inhibitory action of CCK-8 was mainly mediated through the CCK2R pathway. These studies indicate that CCK-8 attenuates humoral immune responses and acts as endogenous immune deactivators in autoimmune diseases.
⺠CCK-8 inhibits IgG1 expression and production in LPS-activated B cells. ⺠CCK-8 inhibits LPS-activated B cell proliferation and differentiation. ⺠CCK-8 regulates transcription factors Blimp1, Pax5, Xbp1 and Bcl6. ⺠The inhibitory action of CCK-8 is mainly mediated by the CCK2R pathway.
